A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome

Abstract

We examine the effects of metformin on insulin resistance (IR) and mood including in adolescent and adult women with polycystic ovary syndrome (PCOS). This trial was conducted in 19 adolescents (age ≤18 years) and 25 adult (age >18 years) women with PCOS. Anthropometric and measurements including, serum glucose, endocrine panel, and lipid profile were performed at baseline. IR was measured by Homeostasis Model Assessment IR (HOMA-IR). Anxiety and depression were measured by Beck’s Anxiety (BAI) and Depression Inventories (BDI-II). All tests were repeated after a 90-day treatment with metformin (1,500 mg/day). The severity of depression and anxiety decreased after 90-day treatment with metformin in women diagnosed with PCOS. The BAI scores were higher in adolescent group while BDI-II scores were higher in the adult group (p = .016). After 90-day metformin treatment, both BDI-II and BAI scores were decreased by 3.3 and 3.4, respectively (p < .001). Indicators of IR and obesity were improved with this therapy. Although the adolescents weighed lower than the adults, baseline HOMA-IR 5.5 ± 1.7 was higher in this group than 4.4 ± 1.2 in the adult women (p =.022). The findings suggest that metformin decrease IR and improve mood both in adolescent and adult women with PCOS.

摘要

本研究观察了二甲双胍治疗青春期及育龄期多囊卵巢综合征胰岛素抵抗及情绪障碍的效果。本试验纳入了19例青春期(年龄≤18 岁) 和25 例育龄期 (年龄 >18岁) 的多囊卵巢综合征患者。观察指标包括人体测量、血糖、血脂、内分泌化验等。按稳态模型公式（HOMA-IR）计算胰岛素抵抗指数。用贝克焦虑量表 (BAI) 和贝克抑郁量表 (BDI-II)评估焦虑和抑郁。二甲双胍(1,500mg/day)治疗90天后再次评估所有指标。通过治疗PCOS女性焦虑抑郁程度改善。育龄组BAI 评分低于青春期组, BDI-II 评分高于青春期组 (p=.016)。BDI-II和BAI评分分别下降3.3 和3.4 (p<.001)。胰岛素抵抗和肥胖均有改善。虽然青春期组的体重低于育龄组, 但是HOMA-IR 5.5 ± 1.7 高于成人组4.4 ± 1.2 (p =.022)。这些结果表明二甲双胍改善了青春期及育龄期多囊卵巢综合征胰岛素抵抗及情绪障碍。

Keywords:

• Metformin
• insulin resistance
• mood
• polycystic ovary syndrome

Acknowledgements

The authors gratefully acknowledge Dr Shole Emami for her assistance with laboratory measurements.

Disclosure statement

No potential conflict of interest was reported by the authors.